BFBrian M. Friedrich

Brian M. Friedrich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brian M. Friedrich has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Anna N. Honko

    Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States

    1 shared publication
  • Darci R. Smith

    United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702, USA

    1 shared publication
  • Gene Garrard Olinger

    Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America

    1 shared publication
  • John C. Trefry

    United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702, USA

    1 shared publication
  • Julia E. Biggins

    Virology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702, USA

    1 shared publication
  • Lisa E. Hensley

    Zoonotic and Emerging Disease Research Unit, United States Department of Agriculture, Agriculture Research Service (USDA-ARS), Manhattan, KS, USA

    1 shared publication

Latest Publications

  • Open Access

    Potential Vaccines and Post-Exposure Treatments for Filovirus Infections

    by Brian M. Friedrich, John C. Trefry, Julia E. Biggins, Lisa E. Hensley, Anna N. Honko, Darci R. Smith, Gene G. Olinger

    Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.